Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
58.4M
-
Shares change
-
+3.51M
-
Total reported value, excl. options
-
$508M
-
Value change
-
+$27.4M
-
Put/Call ratio
-
5.22
-
Number of buys
-
35
-
Number of sells
-
-11
-
Price
-
$8.70
Significant Holders of EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) as of Q2 2024
166 filings reported holding EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock as of Q2 2024.
EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.4M shares
of 69M outstanding shares and own 84.63% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (8.33M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (5.18M shares), BlackRock Inc. (3.76M shares), FRANKLIN RESOURCES INC (3.65M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.59M shares), VANGUARD GROUP INC (2.77M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.5M shares), MORGAN STANLEY (2.25M shares), T. Rowe Price Investment Management, Inc. (2.07M shares), and Essex Woodlands Management, Inc. (1.55M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.